Stockreport

How The OptimizeRx (OPRX) Narrative Is Shifting As Revenue Caution Meets Profit Optimism [Yahoo! Finance]

OptimizeRx Corporation  (OPRX) 
NASDAQ:AMEX Investor Relations: optimizerx.com/investors
PDF OptimizeRx's blended fair value estimate remains steady at US$14.50 per share, so the latest update is more about fine tuning assumptions than resetting the overall pri [Read more]